Search results: (10000)
News Safety and efficacy of dabigatran and other NOACs compared with warfarin in patients with atrial fibrillation – results of a large long-term prospective study
Anticoagulant therapy is key in the prevention of strokes in patients with atrial fibrillation. Until the introduction of new oral anticoagulants (NOACs), warfarin was the first-choice drug for these patients, but unlike NOACs, it requires careful dose titration and effect monitoring. The safety and benefits of using various anticoagulants were examined in the study below.
News Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is indicated. The phase III BE SURE clinical trial focused on comparing the efficacy and safety of bimekizumab and the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab, which currently serves as one of the mainstays of systemic therapy.
News ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses the potential of early treatment of immune thrombocytopenia with thrombopoietin receptor agonists (TPO-RA) in achieving a disease remission sustainable without further therapy.
News The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring
The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab assessed the incidence of clinically significant changes in hematological or biochemical parameters in patients with moderate to severe atopic dermatitis.
News Somapacitan administered once weekly in the treatment of children with growth hormone deficiency – current understanding
Somapacitan is a long-acting derivative of recombinant human growth hormone approved for the treatment of children and adults with growth hormone (GH) deficiency. Dr. Reiko Horikawa from Japan's National Center for Child Health and Development in Tokyo, during the 24th Pediatric Endocrinology Days held in Brno in January 2024, showed that it is a promising therapeutic option for pediatric patients from 3 years of age, thanks to its efficacy, safety, and potential to improve therapy adherence. However, careful long-term monitoring of the safety of long-acting growth hormone (LAGH) products is still necessary.
News Efficacy and Tolerance of Dorzolamide/Timolol Combination With and Without Preservatives in Patients With Elevated Intraocular Pressure
The fixed combination of the carbonic anhydrase inhibitor dorzolamide and the locally acting beta-blocker timolol is indicated for the treatment of elevated intraocular pressure in patients with open-angle glaucoma. The comparison of the efficacy and tolerance of this combination with preservatives, associated among other things with eye irritation, and without them was the subject of the American study presented below.
News Persistent Symptom Control with s.c. Supplementation of C1 Inhibitor in Prophylactic Treatment of HAE
The open-label extension of the COMPACT study with subcutaneous C1 inhibitor in the prophylaxis of hereditary angioedema (HAE) has brought fresh results, shedding light on the treatment's impact on the frequency of attacks and reducing the need for rescue medication.
News Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.
News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.
News Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP
What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of patients with immune thrombocytopenia (ITP)? Italian authors conducted a survey using the Delphi method among selected experts to gather answers to this question and recommendations for clinical practice. Here, we briefly summarize the key points of their consensus published last year.
News Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A
GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol, has demonstrated prophylactic efficacy in patients with severe hemophilia A aged over 12. This product is administered only once every 4 days. In addition to a comparable reduction in the annual bleed rate to standard FVIII prophylaxis products, it has also shown sufficient efficacy in bleeding treatment and a minimal risk of inhibitory antibody formation.
News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?
In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.
News Impact of Dabigatran and Warfarin Treatment on the Risk of Acute Kidney Injury in Patients with Atrial Fibrillation
What clinical characteristics in patients with non-valvular atrial fibrillation may indicate a higher risk of acute kidney injury? Does the modality of anticoagulation therapy play a role in its incidence? These questions were the focus of an extensive retrospective study conducted in an Asian setting.
News How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?
Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral response to COVID-19 vaccination? And does the quantity of post-vaccination antibodies vary depending on the specific vaccine?
News Increased Sympathetic Activity in Patients with Masked Uncontrolled Hypertension
Not all hypertensive patients who have normal blood pressure readings in the doctor's office actually have controlled hypertension. Recent studies suggest that so-called masked uncontrolled hypertension may be linked to increased sympathetic activity.
News From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?
News Incidence of Secondary Malignancies in CLL Patients on FCR Regimen in Central Europe
Chronic lymphocytic leukemia (CLL) represents the most common type of leukemia in Western countries with closely related incidence in Central European states. Since 2000, new therapeutic regimens have been explored and applied in an effort to improve patient prognosis, including the combination of fludarabine, cyclophosphamide, and rituximab (FCR). However, the development of new therapeutic regimens is also associated with concerns about the risk of secondary malignancies.
News Medium to Long-term Results of PFC Sigma Total Knee Arthroplasty
The PFC Sigma knee implant was introduced in 1997. It is the most commonly used system for total knee arthroplasty in England and Wales, accounting for 34.9% of primary implantations in 2006. Studies evaluating medium to long-term implantation outcomes have shown that it is an implant with a high survival rate, low re-implantation rate, and very good clinical results.
Journal articles Transcranial sonography of the medial temporal lobe in Alzheimer’s disease patients
News Potential, Benefits and Proper Use of Probiotics in the Treatment of Acute Gastroenteritis in Children
Clinical studies and experiences from clinical practice have shown the benefits of administering probiotics in the treatment of acute gastroenteritis in children. Pediatrician Dr. Natália Szitányi summarizes the possibilities and rationale for their use in this indication.
News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.
News Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension
Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor, is a widely used antihypertensive. The PPAR-γ receptor plays a role in the genesis of osteoblasts and osteoclasts, and antidiabetic drugs from the thiazolidinedione group, which act as agonists of this receptor, have a known inhibitory effect on bone metabolism and increase the risk of non-traumatic fractures. Knowledge regarding the potential similar effects of telmisartan is limited. The following study compared the effects of telmisartan and losartan (an AT1 blocker without agonistic effect on PPAR-γ) on bone turnover markers in patients with newly diagnosed hypertension.
News Safety and Efficacy of Different Antithrombotic Regimens in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI) require antithrombotic therapy for the prevention of atherothrombosis, stent thrombosis, and cerebrovascular stroke (CVS). The meta-analysis presented below attempted to clarify which antithrombotic regimen is most suitable in terms of safety and efficacy for these patients.
News Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice
In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.
News Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency
For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.